LTA and melanoma: has demonstrated that VN induced by intratumoral administration of low doses of the STING agonist ADU-S100 results in sustained inflammation within the TME of B16 melanomas and local production of homeostatic cytokines/chemokines (LTα, LTβ, LIGHT, CCL19 and CCL21, but remarkably not CXCL13) and pro-inflammatory/pro-TLS mediators (CXCL10, IL-36β, IFNβ) (67).